Pfizer's coronavirus vaccine candidate is 'viable' — but there are some side effects


A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
The first clinical data on the vaccine candidate produced by pharmaceutical giant Pfizer in partnership with German biotech firm BioNTech showed some positive results, although there were side effects, Stat News reports.
The study randomly assigned 45 patients one of three doses of the vaccine — which relies on experimental messenger-RNA technology — or a placebo. The bad news is half of the patients who received the highest dose of the vaccine developed fevers, so they weren't given a second injection, but those who received the two lower doses did receive a second dose. After the follow-up shot, more than 50 percent of the volunteers reported some kind of adverse effect, including fevers and sleep disturbances. That's troublesome, but none of the side effects were considered life-threatening or resulted in hospitalization or disability.
Now, for the good news. The vaccine generated neutralizing antibodies that prevent the coronavirus from functioning, and the levels of those neutralizing antibodies were 1.8 to 2.8-times the levels found in recovered COVID-19 patients.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
No one knows if antibodies lead to immunity, and Pfizer, like every manufacturer with a potential vaccine candidate, will have to conduct larger studies to figure that out. Despite the uncertainty and the side effects, the initial findings represent a promising first step. "We still have a ways to go and we're testing other candidates, as well," said Philip Dormitzer, the chief scientific officer for viral vaccines at Pfizer. "However, what we can say at this point is there is a viable vaccine candidate based on immunogenicity and early tolerability safety data." Read more at Stat News.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
What to know when filing a hurricane insurance claim
The Explainer A step-by-step to figure out what insurance will cover and what else you can do beyond filing a claim
By Becca Stanek Published
-
How fees impact your investment portfolio — and how to save on them
The Explainer Even seemingly small fees can take a big bite out of returns
By Becca Stanek Published
-
Enemy without
Cartoons
By The Week Staff Published
-
FDA to re-evaluate effectiveness of common nasal congestion ingredient
Speed Read
By Justin Klawans Published
-
A flesh-eating bacteria is growing in numbers due to climate change
Speed Read
By Devika Rao Published
-
CDC recommends new RSV vaccine for infants under 8 months
Speed Read
By Devika Rao Published
-
U.S. health agency advises easing federal marijuana restrictions
Speed Read
By Peter Weber Published
-
Medicare drug price negotiations start with 1st 10 drugs, pharmaceutical industry lawsuits
Speed Read
By Peter Weber Published
-
Air pollution may be increasing antibiotic resistance, new research suggests
Speed Read
By Devika Rao Published
-
Tick bites could cause an allergy to red meat, CDC says
Speed Read
By Devika Rao Published
-
The danger of drinking too much water
Speed Read
By Devika Rao Published